Dr Michael Gilbertson

Learn more about Monash Health’s Haematology team.

Dr Michael Gilbertson

Dr Michael Gilbertson is a clinical and laboratory haematologist with a focus on lymphoma and multiple myeloma. He undertook a 2 year lymphoma fellowship at Monash Health and has subsequently been a principal investigator on multiple local and international clinical trials involving new agents and treatment approaches for Hodgkin and Non-Hodgkin lymphomas.

Dr Gilbertson is the current clinical lead for Hodgkin and aggressive Non-Hodgkin lymphoma at Monash Health. gHe is involved in the Australian Leukaemia and Lymphoma Group (ALLG) lymphoma working group and is an adjunct senior lecturer of the Southern Clinical School at Monash University.

Recent Publications

lbornoz SC de, Higgins AM, Petrie D, et al. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies. Blood Adv. 2024;

Binkley MS, Flerlage JE, Savage KJ, et al. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. J. Clin. Oncol. 2024;JCO2301655.

Lewis KL, Jakobsen LH, Villa D, et al. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. J. Clin. Oncol. 2023;41(35):5376–5387.

Barraclough A, England JT, Villa D, et al. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica. 2023;

Cochrane T, Campbell BA, Gangatharan SA, et al. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Intern. Med. J. 2021;51(12):2119–2128.

Hawkes EA, Lee ST, Chong G, et al. Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study. J. Clin. Oncol. 2021;39(15_suppl):7560–7560.